Physician profile
Arnold Lim
NPI 1780611103
$7,747.28
in general payments reported to CMS, 2019-2025
34 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $497 · 2022: $1,250 · 2023: $1,074 · 2024: $2,829 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,382 · Travel and Lodging: $494 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,381.60 |
| Travel and Lodging | $494.00 |
| Education | $124.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,287.60 | 2021-2025 | Krystexxa, Enbrel, Tavneos |
| Janssen Biotech, INC. | $749.32 | 2023-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $662.53 | 2021-2025 | |
| Smith+Nephew, INC. | $652.82 | 2023-2024 | Bone Anchors With Arthroscopic Delivery System, Real Intelligence |
| Ucb, INC. | $641.59 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $530.20 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $495.04 | 2022-2025 | |
| Pfizer INC. | $373.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $276.78 | 2022-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $176.03 | 2021-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $175.48 | 2022-2024 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $172.12 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $165.18 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.51 | 2023-2025 | Cyltezo, Ofev |
| Horizon Therapeutics Plc | $142.46 | 2021-2023 | Krystexxa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $138.75 | 2022-2025 | Actemra, Rituxan |
| Radius Health, INC. | $127.51 | 2021-2022 | |
| Lilly USA, LLC | $123.52 | 2021-2025 | Taltz |
| Sobi, INC | $120.05 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $97.21 | 2023-2025 | Strensiq |
| Organon LLC | $63.29 | 2024-2025 | Hadlima |
| Takeda Pharmaceuticals U.S.A., INC. | $60.80 | 2025 | Hyqvia, Cuvitru |
| Hospira, INC. | $57.38 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $41.85 | 2023-2025 | Idacio |
| Ferring Pharmaceuticals INC. | $35.81 | 2024-2025 | Euflexxa |
| Celltrion USA INC. | $30.84 | 2023 | Yuflyma |
| Sandoz INC. | $30.71 | 2024 | Hyrimoz |
| Kyowa Kirin, INC. | $30.27 | 2023-2024 | Crysvita |
| Depuy Synthes Sales INC. | $29.50 | 2024 | Monovisc, Orthovisc |
| United Therapeutics Corporation | $26.60 | 2024 | Tyvaso |
| Ultragenyx Pharmaceutical INC. | $21.04 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $18.23 | 2024 | Arcalyst |
| Biogen, INC. | $14.30 | 2021 | |
| Tonix Medicines, INC. | $14.08 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.